← All trials
NCT04633733
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 22, 2020
- Primary completion
- Sep 24, 2020
- Completion date
- Jan 31, 2021
- First posted
- Nov 18, 2020
- Last posted
- Nov 18, 2020
- Enrollment
- 24
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Hanlim Pharm. Co., Ltd.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.